Mufemilast

Mufemilast (Heymay005) is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor (IC50 = 80-120 nM) . Mufemilast modulates cytokines upregulated in Behςet’s syndrome (BS) . Mufemilast displays a significant inhibitory effect on TNF-α, which is an important proinflammatory cytokine target in the disease process of psoriasis. Mufemilast can be studied in research for diseases such as rheumatoid arthritis, psoriasis and BS[1][2][3][4][5].

Product Specifications

CAS Number

[1255909-03-5]

Product Name Alternative

Hemay005

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Others

Assay Protocol

https://www.medchemexpress.com/mufemilast.html

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C2=C(NC(C)=O)SC=C2C(N1[C@@H](C3=CC(OCC)=C(C=C3)OC)CS(C)(=O)=O)=O

Molecular Formula

C20H22N2O7S2

Molecular Weight

466.53

References & Citations

[1]Liu Tian, et al., Efficacy and Safety of Mufemilast in Patients with Behçet's Syndrome: A Phase 2, Double-Blind, Placebo-Controlled Trial. |[2]Yilmaz, O., et al., (2024) . New and emerging oral therapies for psoriasis. Drugs in context, 13, 2024-5-6.|[3]Peng, T., et al., (2020) . Advances in the Development of Phosphodiesterase-4 Inhibitors. Journal of medicinal chemistry, 63 (19), 10594–10617.|[4]Liu, X., et al., (2018) . Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. Bioanalysis, 10 (11), 863–875. |[5]Liu, X., et al., (2018) . Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. Bioanalysis, 10 (11), 863–875.